Value, Affordability, and Decision Making
Efficient decisions about allocating health care budgets require assessment of the effects of health care interventions and the value for money they provide. Decision-making processes leading to funding decisions should be structured and evidence-based.
Transferability of HTA
4 January 2017
The second HTAi Asia Policy Forum meeting (2014) was held in Manilla, 10th -11th June 2014. The topic of the meeting was: Transferability of HTA. This…
HTA and Decision Making in Asia: How can the available resources be used most effectively to deliver high quality HTA that can be used by health system decision makers?
4 January 2017
The HTAi Asia Policy Forum meeting 2013 was held in Seoul, 13th -14th June 2013. This was the first of several annual meetings of the HTAi…
Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
1 March 2017
This report presents an analysis of the significant clinical potential of gene therapy and the unique challenges in developing and evaluating evidence on their effectiveness and…
Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
1 February 2017
In 2016 the University of York undertook a review exercise to determine whether NICE’s existing methods and processes are appropriate for assessment of regenerative medicines. The…
Delivering an Outcomes-based NHS: Creating the Right Conditions
1 February 2017
This OHE Seminar Briefing summarises a seminar given by Dr Nicholas Hicks, Co-founder and Chief Executive of COBIC (Capitated Outcomes-Based Incentivised Care). Dr Hicks describes COBIC’s…
Policy Options for Formulary Development in Middle-income Countries
1 January 2017
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. This report presents a framework…
Recently Published: MCDA to Elicit Stakeholders’ Preferences: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma
20 December 2016
This paper uses MCDA to obtain preferences on decision criteria across three stakeholder groups (patients, clinicians and payers) in Italy and then uses these preferences to…
New OHE Research Paper: Uncertainty and Risk in HTA Decision Making
7 December 2016
A new OHE Research Paper has just been published on the topic of uncertainty and risk in health technology assessment (HTA) decision making. The report is…
Eliciting the Relative Value of Life Extension at the End of Life
29 November 2016
Rachel Baker of Glasgow Caledonian University and Koonal Shah of OHE discussed societal viewpoints regarding end of life treatments at a recent seminar.